Researchers at Baylor University are pioneering a groundbreaking technique to target colorectal cancer through the use of genetically engineered bacteria. This innovative approach involves modifying Listeria monocytogenes, a bacterium known for its role as a foodborne pathogen, to transport cancer-fighting proteins directly into tumor cells. Led by Michael S. VanNieuwenhze, PhD, a University Distinguished Professor and chair of the Department of Biology, the study showcases a promising avenue for enhancing cancer treatment.
The Urgent Need for New Cancer Therapies
Colorectal cancer remains a significant health challenge, ranking as the second leading cause of cancer-related deaths in 2025, according to data from the National Cancer Institute. The urgency for novel therapeutic strategies is palpable. With a growing interest in utilizing bacteria as therapeutic agents, VanNieuwenhze and his team have taken a significant step forward by harnessing the unique properties of Listeria monocytogenes. This bacterium’s capability to infiltrate human cells presents a unique opportunity to deliver potent cancer-killing proteins effectively.
A Novel Delivery Mechanism
The researchers’ approach centers on attaching saporin, a well-known cytotoxin, to the surface of Listeria. This innovative design enables the bacterium to deliver saporin directly into cancer cells, where it can exert its lethal effects. VanNieuwenhze explained their strategy succinctly: “What if we could hook saporin on the surface of a bug and let the bug get delivered into the cell as it normally would? We could then take advantage of chemistry inside the cell to release saporin to kill the cancer cell.”
Transforming a Pathogen into a Therapeutic Agent
Despite its negative reputation as a foodborne pathogen, Listeria can be genetically modified to enhance safety and efficacy in cancer treatment. The bacterium has been investigated as a potential cancer therapy since 1994, demonstrating unique characteristics that make it valuable in oncology research. Wyatt Paulishak, a doctoral student involved in the research, highlighted its unique access to intracellular environments, stating, “As a living bug, we can modify it to make it safer and more effective.”
Enhancing Efficacy with Saporin
By chemically linking saporin to Listeria, the team significantly improved its ability to combat cancer. Saporin is harmless until it enters a cell, and the modified Listeria effectively facilitates this entry. Jianan Lyu, another doctoral student on the project, emphasized the importance of proving that saporin was successfully attached to the bacteria. They conducted fluorescent imaging to validate this attachment, allowing them to move forward with in vivo and in vitro testing in mice. The results demonstrated a marked increase in cytotoxicity, confirming the efficacy of this novel delivery method.
Future Directions and Research Goals
Having established proof of concept, VanNieuwenhze and his team are eager to expand their research. They aim to develop genetic strategies that enhance the safety and scalability of this therapeutic approach, with colorectal cancer serving as a key focus. “If a therapeutic were developed from this, you could deliver it orally, in principle,” he noted, pointing toward the exciting possibilities that lie ahead.
Implications for Cancer Treatment
The implications of this research are profound. By utilizing engineered bacteria as a delivery vehicle for cancer therapies, researchers may unlock new pathways for treatment that could significantly improve patient outcomes. The potential for oral delivery represents a paradigm shift in how cancer therapies could be administered, making treatments more accessible and potentially more effective.
Takeaways
- Researchers at Baylor University are using engineered Listeria bacteria to deliver saporin, a potent cancer-killing toxin, directly into colorectal cancer cells.
- The unique properties of Listeria allow it to penetrate human cells, making it an effective tool for targeted cancer therapy.
-
Preliminary results show a significant increase in toxicity against cancer cells, indicating the potential for this method to enhance current treatment options.
-
Future research aims to develop safer and more scalable methods to use this technology in clinical settings.
In conclusion, the innovative use of engineered bacteria to deliver cancer-fighting agents signifies a transformative step in oncology. As research progresses, this approach has the potential to redefine therapeutic strategies and improve the lives of countless patients facing colorectal cancer. The future of cancer treatment appears brighter, driven by the ingenuity of biotechnology and the promise of engineered solutions.
Read more → www.news-medical.net